



[Home](#) > [Life Science Research](#) > [News & Events](#) > [News](#) >

Bio-Rad's QX200™ Droplet Digital™ PCR System Wins the SelectScience Scientists' Choice Award for Best New Life Sciences Product of 2013 at AACR

Bio-Rad's QX200™ Droplet Digital™ PCR System Wins the SelectScience Scientists' Choice Award for Best New Life Sciences Product of 2013 at AACR



Hercules, CA — April 28, 2014 — Bio-Rad Laboratories, Inc.'s [QX200 Droplet Digital PCR \(ddPCR™\) System](#) was awarded the [Scientists' Choice Award](#) for Best New Life Sciences Product of 2013. The award, presented by SelectScience, recognizes the technology that has most significantly impacted life science research in 2013.

"We are seeing more researchers embrace Droplet Digital PCR for a multitude of applications and to have the QX200 System recognized by SelectScience's scientific community is a great reflection of that," said Viresh Patel, senior marketing manager with Bio-Rad's Digital Biology Center.

More than 250,000 members of the SelectScience community were invited to nominate and vote for their favorite new products of 2013. The award was announced at the American Association for Cancer Research (AACR) annual meeting held April 5–9 in San Diego, CA ([watch the video](#)). This was a fitting event for the announcement, as the number of cancer research papers that cite ddPCR nearly quintupled from 2012 to 2013.

Moreover, [one of the more talked about presentations at AACR](#) was given by ddPCR users, Dr. Pasi Jänne and Dr. Cloud Paweletz of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute.

Also at the meeting, Bio-Rad highlighted [promising cancer research applications of ddPCR](#) and previewed the new Automated Droplet Generator and [QX200 AutoDG™ Droplet Digital PCR System](#) ([watch the video](#)). The Automated Droplet Generator simplifies the ddPCR workflow, enabling generation of droplets for 96 samples in less than 30 minutes. Using the AutoDG System, researchers can minimize hands-on time and eliminate user-to-user variability.

This technology has the potential to benefit labs considerably. "With the arrival of the AutoDG System, we hope to make digital PCR both scalable and practical, especially for labs looking to increase the throughput of their ddPCR-based research and translate their discoveries to the clinic," said Patel.

To learn more about ddPCR, please visit www.bio-rad.com/QX200.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,700 people worldwide and had revenues exceeding \$2 billion in 2013. For more information, visit our website at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Press Contacts:

Viresh Patel
Bio-Rad Laboratories, Inc.
925-474-8602
viresh_patel@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com



Left to right: Frank Bizouarn, Carolyn Reifsnnyder, and Viresh Patel accept the SelectScience Scientists' Choice Award for Best New Life Sciences Product of 2013.

In The News

- [The New York Times](#)

